# A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body

> **NCT04267276** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 7 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Part 1: BI 1265162 - intravenous
- **DRUG:** Part 2: BI 1265162 - oral

## Key facts

- **NCT ID:** NCT04267276
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-18
- **Primary completion:** 2020-04-02
- **Final completion:** 2020-04-02
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to the COVID-19 pandemic, the recruitment of new subjects was temporarily halted in March 2020. The study was permanently discontinued in December 2020.
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267276, "A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04267276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*